1. Home
  2. BEAM vs AGO Comparison

BEAM vs AGO Comparison

Compare BEAM & AGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$24.39

Market Cap

2.6B

Sector

Health Care

ML Signal

N/A

Logo Assured Guaranty Ltd.

AGO

Assured Guaranty Ltd.

N/A

Current Price

$68.27

Market Cap

3.0B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
BEAM
AGO
Founded
2017
2003
Country
United States
Bermuda
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
3.0B
IPO Year
2019
2003

Fundamental Metrics

Financial Performance
Metric
BEAM
AGO
Price
$24.39
$68.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
3
Target Price
$52.15
★ $91.00
AVG Volume (30 Days)
★ 1.8M
402.9K
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
★ 2.25%
EPS Growth
★ 82.31
49.34
EPS
N/A
★ 2.80
Revenue
$24,000.00
★ $1,110,000,000.00
Revenue This Year
N/A
$6.21
Revenue Next Year
$29.19
N/A
P/E Ratio
★ N/A
$24.34
Revenue Growth
★ 33.33
27.29
52 Week Low
$20.23
$68.03
52 Week High
$38.26
$92.40

Technical Indicators

Market Signals
Indicator
BEAM
AGO
Relative Strength Index (RSI) 44.05 28.17
Support Level $24.30 N/A
Resistance Level $26.50 $76.96
Average True Range (ATR) 1.12 1.37
MACD 0.08 -0.10
Stochastic Oscillator 54.18 5.43

Price Performance

Historical Comparison
BEAM
AGO

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About AGO Assured Guaranty Ltd.

Assured Guaranty Ltd. provides credit protection products to the United States and international public finance and structured finance markets and manages assets across collateralized loan obligations as well as opportunity funds and liquid funds that build on its corporate credit, asset-based finance, municipal, and healthcare experience. The company operates in two segments: the Insurance segment and the Asset Management segment. The majority of the revenue earned by the company is from the Insurance segment.

Share on Social Networks: